{"companyId":277564,"requestedLanguage":"en","resolvedLanguage":"en","availableLanguages":["en","ja"],"companyName":"Burning Rock Biotech Limited","headOfficeLocation":"Beijing, China","presidentName":"Han Yusheng","companySummary":null,"stockCode":"BNR","currency":"USD","capital":null,"sales":null,"employees":null,"employeesConsolidated":null,"humanCheck":false,"domains":["brbiotech.gcs-web.com"],"businessContents":["Next generation sequencing (NGS) precision oncology testing","Cancer companion diagnostics and early detection services"],"relations":[],"dataSources":[{"detailNumber":1,"url":"https://brbiotech.gcs-web.com/news-releases/news-release-details/burning-rock-announces-licensing-myriad-mychoicer-tumor-testing","scoreAbout":400,"scoreBusiness":300,"scoreGroup":0,"scoreCustomer":0}]}